Opioid treatment 1

Room 5B
In programme
Wednesday, 23 October, 2024 - 16:50 to 18:20
View presentations

About

This session addresses the treatment and healthcare needs of individuals with opioid use disorder (OUD) and explores various opioid agonist treatments (OAT) and heroin-assisted treatment (HAT). Topics include the cost-effectiveness of expanding OAT in Norway, patient experiences with different administration routes of heroin in HAT, and the barriers and facilitators to implementing Scotland’s first HAT service. Additionally, one study examines changes in in-patient healthcare utilisation before and after entering OAT, showing reduced demand for mental and somatic health services after treatment.

Chair

Dietze Paul
  • Professor and co-Director, Disease Elimination Program,
  • Burnet Institute,
  • Melbourne,
  • Australia

Type

Tracks

Keywords

Presentations

Wednesday, 23 October

16:50
Oral presentation

Achieving universal health coverage of opioid agonist treatment in Norway: a cost-utility analysis

16:50 to 18:20
Room 5B
Prayash Chaudhary
Oral presentation

AN IMPLEMENTATION SCIENCE EVALUATION OF SCOTLAND’S FIRST HEROIN ASSISTED TREATMENT (HAT) FACILITY

16:50 to 18:20
Room 5B
Andrew McAuley
Oral presentation

Reduced health care utilization after entering opioid agonist treatment; change in mental and somatic health domains

16:50 to 18:20
Room 5B
Thomas Clausen
Oral presentation

Route-Dependent Subjective Effects of Medical Heroin in HAT: Implications for Treatment Trajectories

16:50 to 18:20
Room 5B
Silvana De Pirro
View the programme